Next week marks the first anniversary of CAMP4 Therapeutics Corp. (CAMP) as a publicly listed company. Since its IPO, the stock has experienced a significant decline and trades around $2 per share, well below its initial offering price of $11.
CAMP4 is a clinical-stage biopharmaceutical company pioneering the development of antisense oligonucleotide (ASO) therapies that target regulatory RNA (regRNA) to boost gene expression and restore normal protein levels in metabolic and central nervous system (CNS) disorders, where key proteins are often underexpressed. Its lead drug candidate is CMP-CPS-001, being developed for the treatment of Urea Cycle Disorders.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com